Systems Biology Approach In The Discovery And Development Of Cyclin-dependent Kinase Inhibitors As New Therapeutics In Oncology And Cardiology | 17085
Journal of Biotechnology & Biomaterials
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Systems biology is an innovative approach, which brings together quantitative experiments, mathematical modelling and
simulations. This approach has accelerated the discovery of new drug targets, development of new drugs and treatment
options. Here the application of systems biology in the discovery and development of cyclin-dependent kinase inhibitors as
new therapeutics with specific examples in oncology and cardiology is discussed. The benefit from the use of mathematical and
computational modelling in drug target identification and validation, lead optimisation and preclinical and clinical development
of drug candidates is illustrated. In addition, the results from recent clinical trials with CDK inhibitors are brought up to date.
Nikolai Zhelev is professor of medical biotechnology and director of CMCBR atAbertay University, Dundee, Scotland. He is also honorary professor in eight
universities in UK, China and Bulgaria. He has been involved in founding four start-up biotech companies and has worked as
head of the departments of
Biochemistry, Cell Biology and Proteomics in Cyclacel Pharmaceuticals Inc. He has published three books in the field of systems biology, cancer research and
treatment, DNA damage and repair as well as papers in high impact journals, including Nature Medicine, with more than 1000 citations.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals